Century Pharmaceuticals is an API manufacturer based in India. It holds 9 active US drug master files across a filed portfolio of 7 molecules. Its filings concentrate with MINSA (CR), BOMRA (BW) and CDSCO (India). Its GMP standing is certified by CDSCO (India). Its most recent recorded inspection, by US FDA, closed on 16 February 2023 as NAI. Customs aggregates show $7.7M of exports covering 518 molecules to 56 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Panchmahal, India | Not on file |
| Gidc, India | Not on file |
| Indianapolis, United States | 1819174 |
| Molecule | Regulators | Docs |
|---|---|---|
| Erythromycin | US FDA | 3 |
| Oxytetracycline | US FDA | 2 |
| Alfacalcidol | SFDA (Saudi Arabia) | 1 |
| Azithromycin | US FDA | 1 |
| Clarithromycin | US FDA | 1 |
| Dorzolamide | US FDA | 1 |
| Roxithromycin | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 3 | None |
| BOMRA (BW) | 2 | None |
| CDSCO (India) | 1 | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $2.2M | 27 |
| 2025 | Not reported | $7.7M | 56 |
| 2024 | Not reported | $11.5M | 50 |
| 2023 | Not reported | $7.2M | 42 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Century Pharmaceuticals comes back tiered against every other supplier able to file there.
Start for free